/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Imunon Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$3.95 0.0115(1.15%) IMNN at 04 Dec 2025 04:35 PM Biotechnology
Lowest Today 3.885
Highest Today 3.95
Today’s Open 3.9
Prev. Close 3.91
52 Week High 35.84
52 Week Low 3.56
Day’s Range: Low 3.885 High 3.95
52-Week Range: Low 3.56 High 35.84
1 day return -
1 Week return -3.45
1 month return +1.55
3 month return -29.67
6 month return +130.67
1 year return +359.13
3 year return +158.94
5 year return -57.27
10 year return -

Institutional Holdings

Geode Capital Management, LLC 0.38

Vanguard Institutional Extnd Mkt Idx Tr 0.35

Fidelity Extended Market Index 0.21

BlackRock Inc 0.15

Vanguard Group Inc 0.13

Fidelity Total Market Index 0.06

XTX Topco Ltd 0.06

Northern Trust Corp 0.06

Baader Bank INC 0.06

State Street Corp 0.06

Fidelity Series Total Market Index 0.05

Northern Trust Extended Eq Market Idx 0.05

NT Ext Equity Mkt Idx Fd - L 0.05

Spartan Extended Market Index Pool F 0.04

SBI Securities Co Ltd 0.04

Renaissance Technologies Corp 0.03

Spartan Total Market Index Pool G 0.02

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.01

NT Ext Eq Mkt Indx Fd DC Lend T3 0.01

Tower Research Capital LLC 0.01

NT Ext Equity Mkt Idx Fd - NL 0.01

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.01

Fidelity Nasdaq Composite Index 0.01

Morgan Stanley - Brokerage Accounts 0.00

BNYM Mellon SL Market Completion UC1 0.00

FMR Inc 0.00

Northern Trust Wilshire 5000 0.00

Bank of America Corp 0.00

Group One Trading, LP 0.00

Federation des caisses Desjardins du Quebec 0.00

Fidelity U.S. Equity Index Ins Trust 0.00

UBS Group AG 0.00

Advisor Group Holdings, Inc. 0.00

Citadel Advisors Llc 0.00

Game Plan Financial Advisors, LLC 0.00

HRT FINANCIAL LLC 0.00

SSgA U.S. Total Market Index Strategy 0.00

Market Status

Strong Buy: 2

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 12.01 M

PB Ratio 2.9562

PE Ratio 0.0

Enterprise Value 7.92 M

Total Assets 9.72 M

Volume 11809

Company Financials

Annual Revenue FY23:125000 0.1M, FY22:500000 0.5M, FY21:500000 0.5M, FY20:500000 0.5M, FY19:500000 0.5M

Annual Profit FY23:null 0.0M, FY22:500000 0.5M, FY21:500000 0.5M, FY20:500000 0.5M, FY19:500000 0.5M

Annual Net worth FY23:-27859519 -27.9M, FY22:-35898000 -35.9M, FY21:-20769000 -20.8M, FY20:-21483561 -21.5M, FY19:-16851533 -16.9M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-167034 -0.2M, Q2/2025:-164674 -0.2M, Q1/2025:-2165092 -2.2M, Q3/2024:null 0.0M, Q2/2024:-185270 -0.2M

Quarterly Net worth Q3/2025:-3429124 -3.4M, Q2/2025:-2740559 -2.7M, Q1/2025:-4102495 -4.1M, Q3/2024:-4845475000 -4845.5M, Q2/2024:-4788017 -4.8M

Fund house & investment objective

Company Information Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Organisation Biotechnology

Employees 25

Industry Biotechnology

CEO Dr. Stacy R. Lindborg Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow